STAT

Christi Shaw, inspired by her sister’s cancer, named CEO of Kite Pharma, Gilead’s anti-cancer unit

Christi Shaw, an Eli Lilly executive, has been named the new head of Kite Pharma, which is focused on treatments that genetically engineer patients’ white blood cells to attack cancer.

Christi Shaw, until Thursday morning the executive in charge of Eli Lilly’s drug division, will become the CEO of Kite Pharma, the unit of biotechnology giant Gilead that is focused on treatments that genetically engineer patients’ white blood cells to attack cancer.

Shaw said she was inspired to take the job because that type of treatment, known as CAR-T, is what she wants to focus

You're reading a preview, sign up to read more.

More from STAT

STAT6 min readSociety
‘Maisie’s Army’: How A Grassroots Group Is Mobilizing To Help Toddlers Access A Lifesaving Drug
A grassroots group called "Maisie's Army" is mobilizing to help toddlers with a rare disease access a lifesaving drug.
STAT4 min readScience
Scientists Routinely Cure Brain Disorders In Mice But Not Us. A New Study Helps Explain Why
Scientists routinely cure brain disorders in mice but not in humans. A new study helps explain why.
STAT5 min readSociety
Opinion: Community Engagement Is Key To Clinical Trial Recruitment And Diversity
Two birds, one stone: improving diversity in clinical trials will simultaneously improve participation.